Effect of the combined preparation Terzhinan® on microorganisms isolated from the urogenital tract of women. In vitro experiment

Cover Page


Introduction. The study is in vitro experiment, aimed to determine antibiotic susceptibility of microorganisms isolated from the urogenital tract of women to the combination of substances included in the preparation Terzhinan.

Methods. In total, 516 microorganism strains isolated from the vagina of reproductive age women have been tested: Candida spp. (n = 83), bacteria of the family Enterobacteriaceae (n = 138), Streptococcus agalactiae (n = 72), Enterococcus spp. (n = 147), Staphylococcus spp. (n = 37), Actinomyces urogenitalis (n = 7), Gardnerella vaginalis (n = 27), Atopobium vaginae (n = 5). Suspensions of each strain in a volume of 0.5 ml (0.5 according to McFarland) were applied onto culture medium (Muller-Hinton Agar or 5% Blood Muller-Hinton Agar). Furthermore, serial dilutions of Terzhinan were applied with a calibrated loop onto three sectors. Petri dishes were then incubated at 37 °С for 24 h. The results were evaluated visually, by measuring growth inhibition zones.

Results. The majority of Candida albicans isolates were susceptible (S) to the preparation, using both undiluted and diluted (10 and 100 times) preparation. Terzhinan without dilution and in the dilution 1:10 was 100% effective against all tested bacteria of the family Enterobacteriaceae. Susceptibility of gram positive bacteria to the antibiotics included in Terzhinan, was 74.1%. All isolates of staphylococci, including Staphylococcus aureus, were susceptible. The frequency of susceptible strains of Streptococcus agalactiae and Enterococcus spp. was 70%. All clinical isolates of Gardnerella vaginalis and Atopobium vaginae were susceptible to the combinations of antibiotics included in the preparation Terzhinan, which is in agreement with data on its high efficiency in the treatment of bacterial vaginosis.

Conclusions. In in vitro experiment, the combined preparation Terzhinan showed high activity against major groups of microorganisms isolated from the vagina including pathological conditions, such as bacterial vaginosis and vulvovaginitis of different etiology.

Alevtina M. Savicheva

Author for correspondence.
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Russian Federation, Saint Petersburg

Honoured Worker of Science of Russia, Professor, MD, Head of the Laboratory of Microbiology

Elena V. Spasibova

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Russian Federation, Saint Petersburg

Bacteriologist of the Laboratory of Microbiology

  • Прилепская В.Н., Межевитинова Е.А., Абакарова П.Р., и др. Лечение вульвовагинитов и вагинозов: клинико-лабораторная эффективность // Гинекология. – 2013. – T. 15. – № 4. – C. 24–29. [Prilepskaya VN, Mezhevitinova EA, Abakarova PR. Vulvovaginitis and vaginosis treatment : clinical and laboratory efficiency. Gynecology. 2013;15(4):24-29. (In Russ.)]
  • Савичева А.М., Захаревич Н.Н., Михнина Е.А. Применение препарата тержинан при вагинальном кандидозе. 1997. [Savicheva AM, Zaharevich NN, Mihnina EA. Primenenie preparata terzhinan pri vaginal’nom kandidoze. 1997 g. (In Russ.)]. Доступен по: https://medi.ru/info/2247. Ссылка активна на 07.05.17.
  • Липова Е.В., Хрзаян Р.С. Эффективность монотерапии бактериального вагиноза и урогенитального кандидоза Тержинаном — комбинированным местнодействующим препаратом // Российский вестник акушера-гинеколога. – 2006. – T. 6. – № 5. – C. 66–68. [Lipova EV, Khrzayan RS. Efficiency of monotherapy for bacterial vaginosis and urogenital candidiasis with the combined topical agent Terginan. Rossijskij vestnik akushera-ginekologa. 2006;6(5):66-68. (In Russ.)]
  • Boyle DC, Barton SE, Uthayakumar S, et al. Is bacterial vaginosis associated with cervical intraepithelial neoplasia? Int J Gynec Cancer. 2003;13(2):159-63. doi: 10.1046/j.1525-1438.2003.13007.x.
  • Vetrano G, Pacchiarotti A, Lombardi G, et al. Correlation between squamous intraepithelial lesions (SILs) and bacterial vaginosis. Eur J Gynaec Oncol. 2007;28(4):310-2.
  • Леваков С.А., Боровкова Е.И., Дабагян Л., Шешукова Н.А. Комплексный подход к лечению пациенток с предраковыми заболеваниями шейки матки в репродуктивном возрасте // Вопросы гинекологии, акушерства и перинатологии. – 2015. – № 3. – C. 13–17. [Levakov SA, Borovkova EI, Sheshukova NA, Dabagyan L. A complex approach to treatment of female patients of reproductive age with precancerous diseases of the cervix. Voprosy ginekologii, akusherstva i perinatologii. 2015;(3):13-17. (In Russ.)]
  • Каратюк Т.И. Эффективность применения комбинированного препарата неомицина, нистатина, преднизолона, тернидазола при проведении деструктивного лечения шейки матки // Клиническая дерматология и венерология. – 2011. – № 5. – C. 78–80. [Karatiuk TI. The efficacy of the application of a composite neomycin-nistatinum-prednisolone-ternidazole preparation for the destructive treatment of uterine cervix. Klinicheskaja dermatologija i venerologija: nauchno-prakticheskij zhurnal. 2011;(5):78-80. (In Russ.)]


Abstract - 189

PDF (Russian) - 45

Copyright (c) 2017 ECO-vector LLC

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.